Evaluation of the Condition of Rheumatoid Arthritis After Treatment

Phase 4

Recruiting

• Conditions: Rheumatoid Arthritis
• Interventions: Drug: The effectiveness of Xeljanz in rheumatoid arthritis patients

• Registration Number: NCT02157012
• Lead Sponsor: Shinshu University

Brief Summary

To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05
• Study First Submitted: 2014-06-01
• Study First Submitted QC: 2014-06-03
• Study First Posted: 2014-06-05
• Status Verified: 2021-09
• Last Update Submitted: 2021-09-20
• Last Update Posted: 2021-09-21
• Primary Completion: 2022-04
• Study Completion: 2025-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Rheumatoid arthritis

Read More

Exclusion Criteria

• Other connective tissue disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
The condition of rheumatoid arthritis	The effectiveness of Xeljanz in rheumatoid arthritis patients	-

Primary Outcome Measures

Name	Time	Method
Change from baseline of clinical evaluation in rheumatoid arthritis	Every month	DAS28, SDAI, Blood testing, Plain radiograph, and Ultrasound will be performed.

Secondary Outcome Measures

Name	Time	Method
Number of participants with adverse events	Every month

Trial Locations

Locations (1)

Yukio Nakamura; 🇯🇵 Matsumoto, Nagano, Japan